Back to News
investment

Aspen Pharmacare Holdings (JSE:APN) Price Target Increased by 21.81% to 146.20

Fintel
Loading...
4 min read
0 likes
⚡ Quantum Brief
Analysts raised Aspen Pharmacare’s (JSE:APN) one-year price target by 21.81% to R146.20 per share, up from R120.02 in February 2026, reflecting revised market expectations. The new target range spans R116.15 to R183.75, but remains 98.86% below the latest closing price of R12,794.00, signaling a potential valuation disconnect or market anomaly. The company’s dividend yield stands at 0.02% with a negative payout ratio of -0.47, indicating unsustainable dividends funded by reserves rather than earnings, paired with a -0.35% three-year dividend growth rate. Institutional ownership plummeted 98.04% last quarter, leaving just two funds holding positions, though their average portfolio allocation rose 657.27% to 0.56%, suggesting concentrated but cautious interest. Invesco’s FTSE RAFI Emerging Markets ETF increased its stake by 61.90% to 75K shares, while Africa Fund held steady at 8K shares, highlighting mixed but selective institutional activity.
AI Audio Summary
0:00 / 0:00
Click to play
quantum computing images (3).jpg
Quantum News · Media Library

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks Aspen Pharmacare Holdings (JSE:APN) Price Target Increased by 21.81% to 146.20 March 28, 2026 — 12:09 pm EDT Written by George Maybach for Fintel-> The average one-year price target for Aspen Pharmacare Holdings (JSE:APN) has been revised to R146,20 / share. This is an increase of 21.81% from the prior estimate of R120,02 dated February 21, 2026. The price target is an average of many targets provided by analysts. The latest targets range from a low of R116,15 to a high of R183,75 / share. The average price target represents a decrease of 98.86% from the latest reported closing price of R12 794,00 / share.

Aspen Pharmacare Holdings Maintains 0.02% Dividend Yield At the most recent price, the company’s dividend yield is 0.02%. Additionally, the company’s dividend payout ratio is -0.47. The payout ratio tells us how much of a company’s income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company’s income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5. The company’s 3-Year dividend growth rate is -0.35% . What is the Fund Sentiment? There are 2 funds or institutions reporting positions in Aspen Pharmacare Holdings. This is an decrease of 100 owner(s) or 98.04% in the last quarter. Average portfolio weight of all funds dedicated to APN is 0.56%, an increase of 657.27%. Total shares owned by institutions decreased in the last three months by 99.72% to 83K shares. What are Other Shareholders Doing? PXH - Invesco FTSE RAFI Emerging Markets ETF holds 75K shares representing 0.02% ownership of the company. In its prior filing, the firm reported owning 29K shares , representing an increase of 61.90%. The firm increased its portfolio allocation in APN by 111.00% over the last quarter. CAFRX - Africa Fund holds 8K shares representing 0.00% ownership of the company. No change in the last quarter. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.Click to Learn MoreThis story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags Stocks Fintel Fintel is a leading provider of financial data and insights for intelligent, data-driven investors. With coverage of over 75,000 listed companies on all major stock exchanges, Fintel has the most comprehensive coverage of global equities at prices individual investors can afford. Find out what Retail is Buying with our Retail Ownership and Funds Flow Leaderboard-> Check out our Gamma Squeeze Leaderboard for High-Conviction Trading Ideas-> For Best Dividend Investments, Check out our Dividend Leaderboard-> More articles by this source-> More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

Read Original

Source Information

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.